Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Clicks: 309
ID: 269154
2018
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In 3 Phase 3 studies, 8 weeks' treatment with glecaprevir/pibrentasivr produced an SVR12 in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis, with virologic failure in less than 1%. The drug combination had a safety profile comparable to 12 week's treatmen …
Reference Key
t2018clinicalefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Asselah T;Kowdley KV;Zadeikis N;Wang S;Hassanein T;Horsmans Y;Colombo M;Calinas F;Aguilar H;de Ledinghen V;Mantry PS;Hezode C;Marinho RT;Agarwal K;Nevens F;Elkhashab M;Kort J;Liu R;Ng TI;Krishnan P;Lin CW;Mensa FJ;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2018
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.